Stephen L. Hauser
University of California, San Francisco
H-index: 124
North America-United States
Top articles of Stephen L. Hauser
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis | Multiple Sclerosis and Related Disorders | Ahmed Abdelhak Kai Antweiler Markus C Kowarik Makbule Senel Joachim Havla | 2024/1/1 |
Tolérance d’ocrelizumab dans la sclérose en plaques: analyse actualisée chez des patients atteints de sclérose en plaques récurrente (SEP-R) et primaire progressive (SEP-PP) | Revue Neurologique | Cathy Chognot Stephen L Hauser Ludwig Kappos Xavier Montalban Élodie Incera | 2024/4/1 |
B Cell-mediated Neurotoxicity in Multiple Sclerosis (P7-6.003) | Chaitrali Saha Amy Zhang Kun Leng Chloe Gerungan Ahmed Abdelhak | 2024/4/14 | |
Impact pour le patient de 10 ans de traitement par ocrelizumab dans la sclérose en plaques: données à long terme des études de phase III OPERA et ORATORIO | Revue Neurologique | Hans-Martin Schneble Martin S Weber Ludwig Kappos Stephen L Hauser Jacqueline A Nicholas | 2024/4/1 |
Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I … | Thomas Leist Stephen Hauser Tobias Derfuss Heinz Wiendl Douglas Arnold | 2024/4/14 | |
An autoantibody signature predictive for multiple sclerosis | Nature Medicine | Colin R Zamecnik Gavin M Sowa Ahmed Abdelhak Ravi Dandekar Rebecca D Bair | 2024/4/19 |
Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007) | Heinz Wiendl Jerome de Seze Amit Bar-Or Jorge Correale Anne Cross | 2023/10/1 | |
10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31. 005) | Stephen Hauser Ludwig Kappos Massimo Filippi Jerry Wolinsky Martin Weber | 2024/4/14 | |
Synaptic Injury in the IPL of the Retina Is a Predictor of Progression in Multiple Sclerosis (P6-6.003) | Christian Cordano Sebastian Werneburg Ahmed Abdelhak Daniel Bennett Alexandra Beaudry-richard | 2024/4/14 | |
Suggested searches | Perspective | Sunkyung Kim Jing Chen Feiya Ou Tian-Tian Liu Suin Jo | 2024/3/4 |
B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials (P9-6.002) | Anne Cross Stephen Hauser Heinz Wiendl Amit Bar-Or Patricia Coyle | 2024/4/14 | |
Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010) | Heinz Wiendl Stephen Hauser Jacqueline Nicholas Jerome De Seze Sven Meuth | 2024/4/14 | |
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension | Journal of neurology | Ludwig Kappos Anthony Traboulsee David KB Li Amit Bar-Or Frederik Barkhof | 2024/2 |
Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis | Cell Reports Medicine | Christian Cordano Sebastian Werneburg Ahmed Abdelhak Daniel J Bennett Alexandra Beaudry-Richard | 2024/4/3 |
Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31. 003) | Gabriel Pardo Stephen Hauser Amit Bar-Or Ralf Gold Xavier Montalban | 2024/4/14 | |
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis | Presented at the CMSC Annual Meeting | Jeffrey A Cohen Stephen L Hauser Anne H Cross Kevin Winthrop Heinz Wiendl | 2023/5/31 |
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity | Neurology: Neuroimmunology & Neuroinflammation | Sasha Gupta Milos Simic Sharon A Sagan Chanelle Shepherd Jason Duecker | 2023/1/19 |
The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies | Martin Weber Ludwig Kappos Stephen Hauser Jacqueline Nicholas Hans-Martin Schneble | 2023/10/1 | |
Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) | Enrique Alvarez Jens Kuhle Ludwig Kappos Tjalf Ziemssen Douglas Arnold | 2023/4/25 | |
A predictive autoantibody signature in multiple sclerosis | medRxiv | Colin R Zamecnik Gavin M Sowa Ahmed Abdelhak Ravi Dandekar Rebecca D Bair | 2023/5/15 |
